794 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
Merck's Keytruda Wins EU Nod for First-Line Head/Neck Cancer http://www.zacks.com/stock/news/631099/mercks-keytruda-wins-eu-nod-for-first-line-head-neck-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-631099 Nov 21, 2019 - Merck's (MRK) Keytruda gets approval in Europe to treat first-line head/neck cancer based on data from the phase III KEYNOTE-048 study.
If Biosimilars Are Struggling, Someone Forgot to Tell Coherus BioSciences https://www.fool.com/investing/2019/11/19/if-biosimilars-are-struggling-someone-forgot-to-te.aspx?source=iedfolrf0000001 Nov 19, 2019 - The company's Neulasta biosimilar has generated $232 million in revenue in the first nine months of 2019, but its growth rate will slow soon.
Merck's Heart Failure Candidate Meets Goal in Phase III Study http://www.zacks.com/stock/news/627569/mercks-heart-failure-candidate-meets-goal-in-phase-iii-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-627569 Nov 19, 2019 - Merck (MRK) and German partner Bayer's vericiguat reduces the risk of heart failure hospitalization or cardiovascular death in patients with worsening chronic heart failure.
Pfizer Gets FDA Approval for Biosimilar of AbbVie's Humira http://www.zacks.com/stock/news/627560/pfizer-gets-fda-approval-for-biosimilar-of-abbvies-humira?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-627560 Nov 19, 2019 - The approval of Humira biosimilar is the fourth U.S. approval of a biosimilar product for Pfizer (PFE) in 2019.
4 Big Biotech Stocks Worth Considering Post Q3 Earnings http://www.zacks.com/stock/news/627538/4-big-biotech-stocks-worth-considering-post-q3-earnings?cid=CS-ZC-FT-analyst_blog|investment_ideas-627538 Nov 19, 2019 - We highlight a few principal players from the biotech sector, which are likely to witness a winning run in the near term.
Bristol-Myers Gets FTC Clearance for Celgene Acquisition http://www.zacks.com/stock/news/625557/bristol-myers-gets-ftc-clearance-for-celgene-acquisition?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-625557 Nov 18, 2019 - Bristol-Myers (BMY) obtains FTC permission for the Celgene acquisition and will divest Otezla to Amgen.
Amarin (AMRN) Gets FDA Panel Nod for Vascepa Label Expansion http://www.zacks.com/stock/news/621335/amarin-amrn-gets-fda-panel-nod-for-vascepa-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-621335 Nov 15, 2019 - Amarin (AMRN) gets favorable FDA Advisory Committee vote to expand the label of Vascepa capsules to reduce cardiovascular risk in patients with persistent elevated triglycerides.
Radius (RDUS) Q3 Earnings Beat Estimates on Tymlos Strength http://www.zacks.com/stock/news/606644/radius-rdus-q3-earnings-beat-estimates-on-tymlos-strength?cid=CS-ZC-FT-analyst_blog|earnings_article-606644 Nov 06, 2019 - Radius (RDUS) reports a narrower-than-expected loss and beats sales estimates in the third quarter of 2019 as Tymlos gains traction.
Top Analyst Reports for Verizon, McDonald's & TOTAL http://www.zacks.com/research-daily/604443/top-analyst-reports-for-verizon-mcdonalds-total?cid=CS-ZC-FT-research_daily-604443 Nov 05, 2019 - Top Analyst Reports for Verizon, McDonald's & TOTAL
AMGN: Cantor Fitzgerald ups to Overweight https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=UD20191105062852 Nov 05, 2019 - Cantor Fitzgerald issues rating change for AMGN

Pages: 123456789...80

<<<Page 4>